Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.96USD
18 Apr 2018
Change (% chg)

$-0.04 (-0.80%)
Prev Close
$5.00
Open
$5.04
Day's High
$5.04
Day's Low
$4.83
Volume
8,773
Avg. Vol
20,867
52-wk High
$7.83
52-wk Low
$4.42

Chart for

About

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine,... (more)
No analyst recommendations are available for .

Overall

Beta: -2.35
Market Cap(Mil.): ₪62.69
Shares Outstanding(Mil.): 139.89
Dividend: --
Yield (%): --

Financials

  TRPX.OQ Industry Sector
P/E (TTM): -- 30.93 33.71
EPS (TTM): -0.30 -- --
ROI: -70.35 13.49 13.09
ROE: -70.35 15.18 14.92

BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program

* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain

* THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN

Mar 20 2018

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

Feb 07 2018

BRIEF-Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary

* THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018

Jan 09 2018

BRIEF-Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement

* THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING

Dec 26 2017

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Dec 04 2017

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Dec 04 2017

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

Nov 10 2017

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

Nov 09 2017

BRIEF-Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer

* Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 02 2017

Earnings vs. Estimates